{"id":"W3041755538","doi":"10.1016/j.annonc.2020.04.061","title":"O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Sorafenib; Internal medicine; Clinical endpoint; Hepatocellular carcinoma; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Clinical trial; Quality of life (healthcare); Cancer; Chemotherapy; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001194085,0.0006107116,0.001227592,0.0002345418,0.0002242237,0.0008709158,0.0002890561,0.0006221611,0.002870977],"category_scores_gemma":[0.00213571,0.0002843121,0.002958429,0.0003585733,0.0003496137,0.0009031245,0.0004590501,0.001438687,0.000411358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006475574,"about_ca_system_score_gemma":0.0007063699,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002273049,"about_ca_topic_score_gemma":0.004972688,"domain_scores_codex":[0.9993337,0.0002668956,0.00006304172,0.0001183079,0.00005083499,0.0001672051],"domain_scores_gemma":[0.999087,0.000223046,0.0002630742,0.00006420773,0.0000542022,0.000308512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8343833,0.007047831,0.0790055,0.0007537952,0.007562329,0.0001298019,0.0002676055,0.0007675392,0.00211908,0.0001545643,0.001977933,0.06583065],"study_design_scores_gemma":[0.2567143,0.2687324,0.4459801,0.0005423067,0.01646688,0.000301388,0.001182468,0.001895457,0.00130153,0.000646902,0.006125551,0.0001107905],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960595,0.002264189,0.00006119677,0.0002376623,0.00007968551,0.0000786414,0.0004803191,0.000006351873,0.0007323959],"genre_scores_gemma":[0.9960127,0.001443196,0.0001355565,0.0005774657,0.0001700576,0.0000961569,0.00084079,0.00000493558,0.000719209],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002870977,"threshold_uncertainty_score":0.009604394,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07461654353671106,"score_gpt":0.3432269850219316,"score_spread":0.2686104414852205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}